ArticleFrontiers in oncology2026
Diagnostic value of a multimodal approach combining inflammatory biomarkers, tumor markers, and ultrasonographic features for borderline ovarian epithelial tumors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: The preoperative differentiation of borderline ovarian epithelial tumors (BOETs) remains challenging. While systemic inflammatory markers such as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR) have shown prognostic value in ovarian cancer, their diagnostic potential in BOETs and the efficacy of a multimodal panel incorporating them have not been fully elucidated. This study aimed to evaluate the predictive value of combining these inflammatory markers with tumor markers (CA125, HE4) and specific ultrasonographic features for the diagnosis of BOETs. Results: The study enrolled 301 patients (101 benign, 99 BOETs, 101 malignant). The NLR and MLR in the BOETs group were significantly higher than in the benign group but lower than in the malignant group ( Conclusions: A multimodal approach integrating PLR/NLR/MLR, CA125, HE4, and the ultrasonographic microcystic pattern significantly enhances the preoperative differentiation of BOETs, and reveal that BOETs have biological characteristics of "inflammatory activation" to a certain extent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.